The Flamma Group Receives Funding from Regione Lombardia

Chignolo D’Isola, Bergamo, Italy – May 5, 2026 – The Flamma Group (“Flamma”) is a global, fully integrated company producing and commercializing small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry. As a preeminent Contract Development and Manufacturing Organization (CDMO) of New Chemical Entities (NCEs) and late-stage intermediates for the Innovator Companies, Flamma is proud to announce that it has received important funding from Regione Lombardia.

GREEN-TECH: Application of innovative, low-environmental-impact technologies for the development and optimization of sustainable chemical processes.

Funded by the regional Program under the European Regional Development Fund 2021/2027 of Regione Lombardia
ERDF ROP 2021-2027

Action: “Support for the implementation of complex research, development, and innovation projects”
Call: “COLLABORA & INNOVA””

Beneficiary: FLAMMA S.P.A.

Description: The project involves the use of process parameters already applied at plant scale and/or still under R&D development as inputs for the creation of a database. This pool of data will be used to develop models for process optimization and for out‑of‑trend and out‑of‑specification investigations. To achieve this goal, the application of Artificial Intelligence (AI) and automation will be essential. Process optimization will be specifically aimed at improving at least one of the following targets: yield, product purity, cycle time, production cost, or the number of failed batches.

Total amount: €552.505,97
Granted aid: €221.002,39

Regional Program under the European Regional Development Fund / ERDF ROP 2021–2027

www.fesr.regione.lombardia.it

Download the press release here

Malvern, PA, USA – February 23, 2026 – The Flamma Group  (“Flamma”), a global, fully integrated, Contract Development and Manufacturing Organization (CDMO) of New Chemical Entities (NCEs) and late stage intermediates for Innovator Companies, announces that its Flamma USA site, located in Malvern, PA, has successfully passed its first US Food and Drug Administration (FDA) inspection.

The pre-approval inspection (PAI) took place over the course of four days for an API that the Flamma USA site will manufacture for a global pharmaceutical company. The inspection covered the entire facility including the manufacturing equipment and quality system, and the site was found to be compliant with all FDA GMP requirements.

The Malvern, PA site was acquired by Flamma in late 2019. Since the acquisition, the site has seen investments over $3M in order to align it with Flamma’s manufacturing and quality standards. The site is focused on early-stage small molecule drug development and manufacture of APIs whether they be small volume, orphan and niche indication APIs.

“This is a tremendous achievement for Flamma USA. Since day one, the site’s goal has been to help customers move their molecules into the clinic for Ph. I studies and onward as quickly as possible,” states Gianmarco Negrisoli, President of Flamma USA. “Our team has worked very hard to bring the site to this level. This milestone serves as a testament to our enduring commitment to the highest standards of quality and regulatory compliance. It affirms our continued capability to strengthen our global presence as a trusted, stable, and dependable partner.” The Flamma USA site consists of 5 GMP kilo-labs, GMP HPAPI suite, GMP pilot plant, GMP clean room along with an R&D lab with 16 hoods. The site allows our team to work efficiently and effectively for customers looking to leverage the entire Flamma global network. Flamma recently hired Craig Dixon as its Site Director. With over 25 years of experience in the industry, Craig brings extensive understanding of the CDMO marketplace, across development, commercial and operations.

Download the press release here

Chignolo D’Isola, Bergamo, Italy – October 21, 2025 – The Flamma Group (“Flamma”), a global, fully integrated company producing and commercializing small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry as well as a preeminent Contract Development and Manufacturing Organization (CDMO) of New Chemical Entities (NCEs) and late stage intermediates for the Innovator Companies, is proud to announce that it has received a 2025 CDMO Leadership Award Europe that will be presented in Frankfurt on October 28, 2025.

Flamma has been recognized as a 2025 CDMO Leadership Awards Europe winner in the Small Molecule API category. Flamma is also a finalist for the Champion Award which will be announced during the rewards ceremony. The Champion Award recognizes the highest-scoring CDMO in each category. You can  learn more at:

https://www.cmoleadershipawards.com/2025-cdmola-europe

“The entire Flamma team is truly honored to receive this award. After being honored earlier in the year in the Small Molecule API- Global category, this additional award shows the industry the commitment that Flamma has made to our customers,” noted Kenneth Drew, Ph.D., VP Flamma USA. “The Outsourced Pharma team goes to great lengths to provide a platform that recognizes excellence in the service side of the Biotech and Pharma industry. Flamma will always continue to work at an award winning level regardless. With that said, it is gratifying to be recognized for our efforts.”

“The 2025 CDMO Leadership Awards Europe is a well-deserved recognition to European organizations that have demonstrated excellence in contract development and manufacturing. These awards are the most important in our industry because they are based on the judgement of biopharma sponsors and the value they place in trusted partnerships,” according to Louis Garguilo, Chief Editor, Outsourced Pharma Flamma will proudly accept the awards at the CDMO Leadership Awards Europe Ceremony and Reception on October 28, 2025 at the Steigenberger Frankfurter Hof in Frankfurt.

Download the press release here

Chignolo D’Isola, Bergamo, Italy – June 26, 2025 – The Flamma Group (“Flamma”) is a global, fully integrated company producing and commercializing small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry. As a preeminent Contract Development and Manufacturing Organization (CDMO) of New Chemical Entities (NCEs) and late-stage intermediates for the Innovator Companies, Flamma is proud to announce that has received important funding from Regione Lombardia.

INVESTMENT MEASURE – BUSINESS DEVELOPMENT LINE – FLAMMA S.P.A.
ID 4826943

Funded by the regional Program under the European Regional Development Fund 2021/2027 of Regione Lombardia
ERDF ROP 2021-2027

Action: 1.3.3 “Support for SME investments”

Call: “INVESTMENTS – BUSINESS DEVELOPMENT LINE”

Beneficiary: FLAMMA S.P.A.

Description: industrial development project for the Bulciago site, with the implementation of an advanced DCS system for the automated and integrated control of plants. The goal is to improve supervision and interconnection of the machinery, ensuring remote management, safety, and compliance with standards. The project involves an initial investment of 1,5 million euros, involving over 25 reactors and various departments with new infrastructure, temperature regulation, and instrumentation. The transition will take place gradually, with the switch to the Siemens PCS7 platform and the modernization of electrical and control panels.

Total amount: €1,500,000.00
Granted aid: €235,680.94

Regional Program under the European Regional Development Fund / ERDF ROP 2021–2027
www.fesr.regione.lombardia.it

Download the press release here

Chignolo D’Isola, Bergamo, Italy – June 23, 2025 – The Flamma Group  (“Flamma”) is a global, fully integrated company producing and commercializing small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry. As a preeminent Contract Development and Manufacturing Organization (CDMO) of New Chemical Entities (NCEs) and late stage intermediates for the Innovator Companies, Flamma celebrated the Grand Opening of its new state-of-the-art cGMP plant in Dalian, China. This milestone aligns with the company’s broader strategy to invest significantly across its global network which included its continued expansion within Italy.

“Flamma has been present in the Chinese market for over 30 years. Initially, we focused on sourcing key raw materials directly to secure the supply chain. We then established our own R&D laboratory in China which ultimately led to the formation of Flamma Honkai in Dalian in 2012. We are extremely proud of what we’ve accomplished over the past 17 years of operations in Dalian. With Honkai being a fully owned and run subsidiary, we’ve been able to combine Flamma’s core values and expertise with the efficiency of the Honkai management team, leading to a 30-fold increase in turnover, Chinese FDA approval, and significant market growth,” says Dr. GianPaolo Negrisoli, President and CEO.

Founded 75 years ago in Bergamo, Flamma continues to represent the excellence of Italian manufacturing and innovation. “As we inaugurate this major site in Dalian, we also reaffirm our roots,” states GianMarco Negrisoli, Executive Director – Corporate Development. “This global expansion complements the substantial investments we are making in Italy, including significant facility upgrades, capacity increases, and continued recruitment of high caliber talent. Flamma plans to reinvest $200 million worldwide over the next five years to grow our manufacturing capacity, technology and capabilities, reinforcing the synergy between its Italian heritage and global outlook.”

Download the press release here

About Flamma:

Founded in 1950, Flamma is a global, fully integrated CDMO specializing in small molecule development and manufacturing. With facilities in Italy, China, and the USA, we deliver Chemistry with a Human Touch—combining scientific precision, strategic thinking, and a deeply collaborative approach.

https://www.FlammaGroup.com

https://www.linkedin.com/company/flamma-spa

https://twitter.com/flammagroup

https://www.facebook.com/TheFlammaGroup

Chignolo D’Isola, Bergamo, Italy – April 15, 2025 – The Flamma Group  (“Flamma”), a global, fully integrated company producing and commercializing small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry as well as a preeminent Contract Development and Manufacturing Organization (CDMO) of New Chemical Entities (NCEs) and late stage intermediates for the Innovator Companies, recently published an article in Organic Process Research & Development (OPRD). ORPD is widely recognized as a leading journal focusing on sustainable and safe syntheses for industrial-scale applications.

Flamma has published the article titled “Solvent Eco-Impact Metric: A Tool for Chemists to Drive Sustainability in Chemical Processes across Safety, Health, Waste, and Environmental Aspects” in Organic Process Research & Development (OPRD). The article is published open access, making it freely available to the global scientific and industrial community and is available here https://doi.org/10.1021/acs.oprd.4c00546.

This article discusses a new method for assessing eco-impact by using both quantitative and qualitative data, focusing on process sustainability. The metric offers actionable guidelines to support daily process development, aiding in achieving ESG objectives. The new approach is designed to adapt to the specific needs of any chemical or pharmaceutical company, without aiming to introduce a new industry standard.

The article was published on OPRD as open source, allowing Flamma to reach a broader audience and build a stronger reputation in the CDMO industry. In the latest version of the process evaluation tools are already implemented the new approach and metrics in the “Eco-Impact” worksheet.

“This publication marks an important milestone for Flamma and reflects our concrete approach to supporting ESG goals through innovation in process chemistry,” notes Federico Della Negra, who co-authored the publication with Massimo Verzini and Marco Ferrara.

Marco Ferrara adds “The article presents a practical, adaptable tool developed and routinely used at Flamma to quantify and reduce the eco-impact of API manufacturing. This metric helps identify key areas for improvement and supports chemists in making informed, sustainable choices that align with ESG goals.”

Flamma is proud to take this significant step forward in its commitment to greener, more efficient process development.

Download the press release here

Chignolo D’Isola, Bergamo, Italy – March 19, 2025 – The Flamma Group  (“Flamma”), a global, fully integrated company producing and commercializing small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry as well as a preeminent Contract Development and Manufacturing Organization (CDMO) of New Chemical Entities (NCEs) and late stage intermediates for the Innovator Companies, received a 2025 CDMO Leadership Award that was presented in New York City on March 19, 2025.

Flamma was recognized as a 2025 CDMO Leadership Awards winner in the Small Molecule API – Global category. In addition to the CDMO Leadership Awards, Outsourced Pharma presented a Best In Class Award in order to capture more of what the CDMO industry and professionals excel at every day.

The Best In Class Award recognized additional qualities that innovator companies value when selecting a partner. Finalists and winners were calculated using the same survey results that support the Leadership Awards. Flamma was named the winner of the Best On-Time Delivery category over the other nominees Siegfried, WuXi Biologics, and WuXi STA.

You can learn more as well as see the other award winners at https://www.cdmoleadershipawards.com

“Flamma is delighted to be recognized for not only its CDMO Leadership Award in the Small Molecule API- Global category but to also be selected for a Best In Class award for On-Time Delivery shows the industry how dedicated we are to service our customers. We strive to provide fair quotes with realistic delivery times in order to illustrate our commitment to the customer,” said Kenneth Drew, Ph.D., VP Flamma USA. “This is a testament to our employees who are the reason we are successful. Flamma is proud to be celebrating 75 years of industry service. We endeavor to be the CDMO that pharmaceutical and biotech companies can depend on for quality service and delivery of their small molecule”.  

Flamma accepted these awards at the CDMO Leadership Awards Ceremony and Reception on March 19, 2025 at the POOL in New York City.

View video from event

Download press release

Chignolo D’Isola, Bergamo, Italy – March 10, 2025 – The Flamma Group  (“Flamma”), a global, fully integrated company producing and commercializing small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry as well as a preeminent Contract Development and Manufacturing Organization (CDMO) of New Chemical Entities (NCEs) and late stage intermediates for the Innovator Companies, is proud to announce that it has received a 2025 CDMO Leadership Award that will be presented in New York City on March 19, 2025.

Now in its 14th year, Outsourced Pharma’s CDMO Leadership Awards uses real customer data to evaluate various strengths and weaknesses of CDMOs. This year, almost 300 survey respondents evaluated 210 CDMOs. It should be noted that the respondents based their evaluations on companies with which they have worked on an outsourced project within the past 24 months.

An enhanced scoring methodology was developed in collaboration with Outsourced Pharma’s research partner, Orientation Marketing. This methodology was applied to four categoriesSmall Molecule API, Biologics, Cell & Gene Therapy, and Small Molecule Dosage Form. The four categories were then further divided to recognize top CDMOs in three service regions: Global, North American, and International.

Flamma has been recognized as a 2025 CDMO Leadership Awards winner in the Small Molecule API – Global category. You can  learn more as well as see the other award winners at https://www.cdmoleadershipawards.com

“Flamma would like to express strong gratitude to Outsourced Pharma for continuing to shine a light and recognizing deserving CDMOs for their tireless work to help innovator companies in Biotech and Pharma who are trying to bring new medicines to the world,” noted Kenneth Drew, Ph.D., VP Flamma USA. “As Flamma celebrates 75 years of service to the industry, we strive to be a good partners. We obviously could not be selected without those customers who took the time to complete the survey and we thank all whom participated. Our passion continues and we will continue to work at an award winning level always.”

Flamma will proudly accept the awards at the CDMO Leadership Awards Ceremony and Reception on March 19, 2025 at the POOL in New York City.

Download press release

Chignolo D’Isola, Bergamo, Italy – October 7, 2024 – The Flamma Group  (“Flamma”), a global, fully integrated company producing and commercializing small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry, in order to effectively support and consolidate its remarkable growth, proudly announces the appointment of Giorgio Bertolini as the new General Manager for Italy.

Giorgio will report directly to the Flamma’s CEO, Gian Paolo Negrisoli. As General Manager Italy, he will be responsible for the objectives and the economic results of Flamma’s three Italian sites. He will coordinate and harmonize the operational and management activities across the three sites  ensuring that all their activities are aligned with the management’s long term strategic vision and the company values

Along with a degree in chemistry, Giorgio has more than 30 years of experience where he has held significant roles with other CDMOs within the pharmaceutical industry. Giorgio brings a deep knowledge of our business, extensive experience and broad vision. We are confident that he will add significant value within the Flamma Group.

Giorgio notes “I am truly honored to join Flamma, a company renowned for its rapid expansion in reaction capabilities, advanced technological platforms, and growing international presence. I’m stepping onto a train that’s already in motion, but I’m fully committed to driving further growth and ensuring that we continue to deliver products and projects to our customers on time and in full.”

Gian Paolo Negrisoli, Flamma CEO, commented “As Flamma continues to grow, we will continue to be proactive in order to bring value to our customers. We are confident that Giorgio will use his experience to help Flamma achieve the goals we have in place. We are excited for the future and know that Giorgio will be instrumental in our continued growth and success.”

Download press release

Chignolo D’Isola, Bergamo, Italy – August 15, 2024 – The Flamma Group  (“Flamma”), a global, fully integrated company producing and commercializing small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry as well as a preeminent Contract Development and Manufacturing Organization (CDMO) of New Chemical Entities (NCEs) and late stage intermediates for the Innovator Companies, announced a cooperative agreement with Seven Star Pharmaceutical Services (SS) to expand its solid state science services.

This collaboration will allow Flamma to service customers more effectively by identifying the proper version of their API. By looking at a variety of areas such as salt & co-crystal selection, crystallization development, polymorph investigation, and pre-formulation evaluation, this partnership will look to solve typical problematic areas in the development of new drugs.

Gianmarco Negrisoli, President Flamma USA, commented “We have been working with Seven Star for several years and felt that it was time to formalize our collaboration. The proximity to Flamma USA coupled with the expertise in house at Seven Star will be beneficial to existing and new customers. Solving crystallization issues early on can speed development and scale up which, in turn, is beneficial to all parties involved.”

“Working with the Flamma USA team has been rewarding. Our ability to turn projects around quickly has helped their customers succeed in their attempts to get their molecule into the clinical. We are very proud to be part of the process to bring new drugs forward,”  says Sathyanarayana ‘Reddy’ Perumalla, Ph.D.,  Founder and Director, Seven Star Pharmaceutical Services. Flamma USA offers customers an easy entry point into the Flamma Group. Specializing on early stage & pre-clinical development of new drugs, the Malvern, PA facility can leverage Flamma Italy and Flamma Honkai to provide multiple options for securing ones supply chain.

Download press release here